In young patients with essential thrombocythemia and early significant atherosclerotic disease but no thrombotic history, would you consider the addition of cytoreductive therapy?  

Would the presence of JAK2 versus CALR versus MPL influence this decision? What if there are other risk factors for cardiovascular disease?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Taussig Cancer Institute
I agree! Without clear evidence in these cases, we...
at UT Southwestern Medical Center
Thanks for your expertise and time!
Sign in or Register to read more